دانلود مقاله ISI انگلیسی شماره 59544
ترجمه فارسی عنوان مقاله

مهار بازدارندگی پاسخ ناگهانی در بیماران مبتلا به ریسپریدون: مقایسه با داروهای ضد روانپریشی معمولی

عنوان انگلیسی
Prepulse inhibition of the startle response in risperidone-treated patients: comparison with typical antipsychotics
کد مقاله سال انتشار تعداد صفحات مقاله انگلیسی
59544 2002 8 صفحه PDF
منبع

Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)

Journal : Schizophrenia Research, Volume 55, Issues 1–2, 1 May 2002, Pages 139–146

ترجمه کلمات کلیدی
ریسپریدون، جنون جوانی، ضد روانپزشکی، مهار پیش قاعدگی
کلمات کلیدی انگلیسی
Risperidone; Schizophrenia; Antipsychotics; Prepulse inhibition

چکیده انگلیسی

Individuals with schizophrenia are known to show deficits in prepulse inhibition (PPI) of the startle response. PPI refers to a response suppression in reaction to a strong startling stimulus, if preceded briefly by a weak non-startling stimulus and represents a well-established animal model to investigate information processing deficits in schizophrenia. This study examined PPI of the startle acoustic response in schizophrenic patients given typical antipsychotics or a second generation atypical antipsychotic, risperidone, using a naturalistic between-subjects design. Two groups of male schizophrenic patients: (i) stable on a range of typical antipsychotics (n=20), and (ii) stable on risperidone (n=10) were tested for PPI (prepulse-to-pulse intervals: 30, 60, and 120 ms, prepulses 15 dB above the background) of the acoustic startle response, and compared with a group of healthy male subjects (n=20). Patients on typical antipsychotics showed significantly less PPI with 30 and 60 ms prepulse trials than healthy subjects. Risperidone-treated patients did not differ from healthy subjects for PPI with any prepulse trials. Further longitudinal within-subject studies are now required to examine whether risperidone is superior to typical antipsychotics in improving information processing functions, as assessed by PPI of the acoustic startle response, in treatment-responsive male patients with schizophrenia.